Patient-friendly, non-technical summary of research papers

August 2026 Research Update

This report covers research on Alstrom Syndrome published in PubMed in August 2026. For other months, see all research updates.

Last update: September 1, 2026

At a glance

Diabetes medicine add-on

In two siblings, ertugliflozin was followed by lower HbA1c.

Early then later shift

Insulin resistance improved early, then increased later.

Reported side effects

The report did not describe ketoacidosis or low blood sugar.

Small, mixed findings

In a very small report, blood sugar measures improved at first. Liver tests were mostly stable, but later signs suggested fibrosis progressed.

Overview

This month, the literature for Alstrom syndrome included one very small report about a diabetes medicine.

In two siblings, adding ertugliflozin (a diabetes drug that helps the body pass extra sugar into the urine) was followed by lower long-term blood sugar (HbA1c) and lower fasting glucose. Insulin resistance measures improved early in follow-up. Later measurements rose again, which suggests the change may not stay steady over time.

Some blood fat measures also moved in a helpful direction, including total cholesterol in both siblings. Over about 11 months, the report did not describe diabetic ketoacidosis, low blood sugar, or genital or urinary infections.

Kidney filtration and liver blood tests were described as generally stable, with some ups and downs. Liver imaging stayed consistent with fatty liver. Later measurements suggested liver scarring (fibrosis) progressed despite treatment. Overall, the report adds an early signal to watch and points to outcomes future studies should measure in larger groups.

Get the monthly update by email

Subscribe here to receive an email when a new monthly Alström syndrome update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).

Research topics this month

This month brought one early, very small report suggesting that ertugliflozin (a diabetes drug that helps the body pass extra sugar into the urine) may improve blood sugar control in some people with Alstrom syndrome. The improvements were seen soon after starting the medicine, and then some measures drifted later, which matches the idea that metabolic control can change over time in this condition. Because this was only two people in the same family and there was no comparison group, it cannot show how well the drug would work for most patients, but it adds a concrete signal worth tracking in future research.

In the report, both siblings had lower HbA1c (a long-term blood sugar measure) and lower fasting glucose after ertugliflozin was added to their existing diabetes treatment. Their insulin resistance measure (HOMA-IR) also dropped early, although later values rose again, showing that the change may not be steady over time. Some blood fat measures improved too, including total cholesterol in both siblings and uric acid in one sibling.

Safety looked reassuring within the limits of the report, with no ketoacidosis, low blood sugar, or genital/urinary infections described during follow-up. Kidney filtration and liver blood tests were described as generally stable with fluctuations, and liver imaging remained consistent with fatty liver; later measurements suggested mild-to-moderate fibrosis progression despite treatment. This mix of stable lab safety signals alongside ongoing liver changes highlights that metabolic improvements do not automatically mean all organ complications are halted.

For patients and caregivers, this report mainly adds early research information rather than a clear answer about what to expect. It suggests that an SGLT2 inhibitor (ertugliflozin) might help some people with Alstrom syndrome reach better blood sugar levels and possibly improve some cholesterol-related labs, at least for a period of time, but it is not strong enough evidence to predict results for others. It also leaves uncertainty about longer-term effects, since insulin resistance measures changed over time and liver stiffness still progressed in later follow-up. Right now, its main value is showing what outcomes future studies should measure (blood sugar, insulin resistance, lipids, kidney safety, and liver changes) in larger groups.

Limitations

Only two related people were reported, so results may not generalize.
There was no comparison group, so changes cannot be clearly attributed to the medicine.
Follow-up was limited to about 11 months, and some measures shifted over time.

Important information

This document summarizes recent research from PubMed-indexed publications using automated methods.
It is intended for educational purposes and does not replace medical advice.
Links to the original studies are provided via PubMed, where readers can explore abstracts and, when available, access full-text articles.
Some studies may include additional details that were not accessible for this summary.
Readers seeking more complete detail or context may find it helpful to review the original studies directly.